Instead of just quoting what Celldex says about their preclinical work with the APC technology, why don't you comment about the Phase I trial results?
Did the antibodies actually generate high antigen-specific activated T-cell levels and CD4 levels? How do those early results compare with other vaccines against the same target? Any positive outcomes for the patients?
"Responsible Party: Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
It certainly is. Are you aware that Pfizer after testing CDX-110 in the clinic for GBM and in the lab for other indications decided in September to abandon the vaccine?
<And MEDAREX INC own 2,960,848 shares (with shares Out. 32.1M).
Medarex ( former NASDAQ symbol: MEDX ) is an American biotechnology company owned by Bristol Myers Squibb and based in Princeton, New Jersey. The company has manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. Medarex specializes in therapeutic products based on monoclonal antibodies.>
nice review of the basic science and for the most part you are spot on! you may want to check the Medarex position which we have discussed numerous times on this board was SOLD around the time BMY bought out Medarex! Marrucci the CEO has confirmed this!
I would not wait too long to get your position started as there are still a few hours left today! LOL!